<DOC>
	<DOCNO>NCT02557646</DOCNO>
	<brief_summary>The purpose open-label , non-randomized , single-arm , multicentre observational study investigate influence cumulative dose ( total administer dose/ plan dose ) ribavirin sustain virologic response ( SVR ) participant receive combination therapy pegylated interferon alfa-2a ( Pegasys ) ribavirin ( Copegus ) .</brief_summary>
	<brief_title>An Observational Study Assess Effect Cumulative Ribavirin Dose Participants With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Participants serologically confirm chronic hepatitis C Participants use accept double method contraception Participants approve national treatment guideline Interferon Committee combine pegylated interferonribavirin treatment Contraindications summary product characteristic pegylated interferon alpha2a ribavirin Participants previously treat pegylated interferon and/or ribavirin Hepatitis B Human Immunodeficiency Virus coinfections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>